Matched comparison of therapeutic DLI and second allogeneic transplantation after relapse of acute leukemia or MDS - Takeaways - MDSpire

Matched comparison of therapeutic DLI and second allogeneic transplantation after relapse of acute leukemia or MDS

  • By

  • Alexander C. Angleitner

  • Markus Maulhardt

  • Justin Hasenkamp

  • Judith Büntzel

  • Gerald Wulf

  • June 11, 2026

  • 0 min

Share

  • 1

    Relapse is the primary cause of treatment failure after allogeneic hematopoietic cell transplantation in acute leukemia and myelodysplastic syndromes.

  • 2

    The study analyzed 85 adults who received either therapeutic donor lymphocyte infusion or second allo-HCT after relapse from 2010 to 2022.

  • 3

    Overall survival did not significantly differ between therapeutic DLI and second allo-HCT, with median OS of 0.92 years and 0.61 years, respectively.

  • 4

    DLI was associated with higher relapse-related mortality, while second allo-HCT showed a trend toward increased non-relapse mortality.

  • 5

    The findings suggest that treatment should be individualized, and larger multicenter studies are necessary to refine patient selection.

Original Source(s)

Matched comparison of therapeutic DLI and second allogeneic transplantation after relapse of acute leukemia or MDS

  • by Alexander C. Angleitner, Markus Maulhardt, Justin Hasenkamp, Judith Büntzel, Gerald Wulf

  • June 11, 2026

Related Content

Author Correction: Transformer patient embedding using electronic health records enables patient stratification and progression analysis

Risk factors for esophageal stricture after circumferential endoscopic submucosal dissection: a preliminary, multicenter, retrospective, case-control study

Optimising individualised treatment decisions for locally advanced thymoma: precision selection of minimally invasive surgery and postoperative adjuvant radiotherapy